Efficacy and Safety of Olmesartan Medoxomil in Patients with Stage 1 Hypertension: Blood Pressure Lowering and Goal Achievement

2010 ◽  
Vol 122 (6) ◽  
pp. 57-67 ◽  
Author(s):  
F. Wilford Germino
2019 ◽  
Vol 37 (8) ◽  
pp. 1567-1573 ◽  
Author(s):  
Abdul Salam ◽  
Emily R. Atkins ◽  
Benjumin Hsu ◽  
Ruth Webster ◽  
Anushka Patel ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (5) ◽  
pp. e028698 ◽  
Author(s):  
Kazem Rahimi ◽  
Dexter Canoy ◽  
Milad Nazarzadeh ◽  
Gholamreza Salimi-Khorshidi ◽  
Mark Woodward ◽  
...  

IntroductionPrevious research from the Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) and others has shown that pharmacological blood pressure (BP)- lowering substantially reduces the risk of major cardiovascular events, including ischaemic heart disease, heart failure and stroke. In this new phase, the aim is to conduct individual patient-level data (IPD) meta-analyses involving eligible BP-lowering randomised controlled trials (RCTs) to address uncertainties relating to efficacy and safety of BP-lowering treatment.Methods and analysisRCTs investigating the effect of pharmacological BP-lowering, with a minimum of 1000 patient-years of follow-up in each trial arm, are eligible. Our systematic review identified 100 potentially eligible trials. We requested their investigators/sponsors to contribute baseline, follow-up and outcomes data. As of June 2018, the collaboration has obtained data from 49 trials (n=315 046 participants), with additional data currently in the process of being transferred from four RCTs (n=34 642 participants). In addition, data harmonisation has commenced. Scientific activities of the collaboration are overseen by the Steering Committee with input from all collaborators. Detailed protocols for individual meta-analyses will be developed and registered on public platforms.Ethics and disseminationEthics approval has been obtained for this new and extended phase of the BPLTTC, the largest collaboration of de-identified IPD from RCTs. It offers an efficient and ethical manner of re-purposing existing data to answer clinically important questions relating to BP treatment as well as methodological questions relating to IPD meta-analyses. Among the immediate impacts will include reliable quantification of effects of treatment modifiers, such as baseline BP, age and prior disease, on both vascular and non-vascular outcomes. Analyses will further assess the impact of BP-lowering on important, but less well understood, outcomes, such as new-onset diabetes and renal disease. Findings will be published in peer-reviewed medical journals on behalf of the collaboration.


2017 ◽  
Vol 35 (7) ◽  
pp. 1481-1495 ◽  
Author(s):  
Jean-Jacques Mourad ◽  
Celso Amodeo ◽  
Martine de Champvallins ◽  
Romualda Brzozowska-Villatte ◽  
Roland Asmar

2019 ◽  
Vol 37 (9) ◽  
pp. 1768-1774 ◽  
Author(s):  
Abdul Salam ◽  
Raju Kanukula ◽  
Emily Atkins ◽  
Xia Wang ◽  
Shariful Islam ◽  
...  

The Lancet ◽  
2015 ◽  
Vol 385 (9982) ◽  
pp. 2047-2056 ◽  
Author(s):  
Suetonia C Palmer ◽  
Dimitris Mavridis ◽  
Eliano Navarese ◽  
Jonathan C Craig ◽  
Marcello Tonelli ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document